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Abstract: During development, melanocyte progenitors originate from the neural crest, a transient em-
bryonic structure in vertebrates that gives rise to a variety of cell types including neurons and glia
of the peripheral nervous system, smooth muscle cells of the cardiovascular system, chondrocytes and
osteoblasts of the craniofacial elements, and pigment cells in the skin. In this chapter, we describe a
method for the differentiation of multipotent embryonic neural crest stem cells into differentiated pig-
mented melanocytes by using in vitro explant culture system. This protocol allows the dissection of
genetic and cellular mechanisms regulating neural crest stem cell and melanocyte development. Based
on this knowledge it is possible to make predictions about processes that might also be implicated in
melanoma initiation and progression.
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Abstract	  	  In	   recent	   years,	   it	   has	   become	   apparent	   that	   the	  mechanisms	  by	  which	   cancer	  cells	  self-­‐renew,	  migrate	  and	  invade,	  resemble	  their	  embryonic	  counterparts	  and	  that	  during	  the	  steps	  of	  the	  initiation	  and	  progression	  cancer	  cells	  can	  reprogram	  into	  embryonic-­‐like	  cells	  (1,	  2).	  Melanoma	  is	  one	  of	  the	  most	  aggressive	  human	  cancers	  and	  it	  is	  believed	  to	  originate	  from	  the	  genetic	  deregulation	  of	  the	  cells	  of	  the	   melanocytic	   lineage.	   As	   many	   other	   cancers,	   melanoma	   cells	   display	   the	  expression	  of	  developmental	  genes	  and	  can	  be	  reprogrammed	  when	  exposed	  to	  embryonic	   environment	   (3,	   4).	   During	   development,	   melanocyte	   progenitors	  originate	   from	   the	  neural	   crest,	   a	   transient	   embryonic	   structure	   in	   vertebrates	  that	   gives	   rise	   to	   a	   variety	   of	   cell	   types	   including	   neurons	   and	   glia	   of	   the	  peripheral	   nervous	   system,	   smooth	  muscle	   cells	   of	   the	   cardiovascular	   system,	  chondrocytes	  and	  osteoblasts	  of	   the	  craniofacial	  elements,	  and	  pigment	  cells	   in	  the	   skin.	   In	   this	   chapter,	   we	   describe	   a	   method	   for	   the	   differentiation	   of	  embryonic	   neural	   crest	   stem	   cells	   into	   melanocytes.	   This	   protocol	   allows	   the	  dissection	  of	   genetic	  and	  cellular	  mechanisms	   regulating	  neural	   crest	   stem	  cell	  and	  melanocyte	   development.	   Based	   on	   this	   knowledge	   it	   is	   possible	   to	  make	  predictions	  about	  processes	  that	  might	  also	  be	  implicated	  in	  melanoma	  initiation	  and	  progression.	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1. Introduction	  	  Neural	  crest	  cells	  originate	  in	  the	  ectoderm	  at	  the	  margins	  of	  the	  neural	  tube	  and,	  after	   a	   phase	   of	   epithelial-­‐mesenchymal	   transition	   and	   extensive	   migration,	  settle	   down	   in	   different	   parts	   of	   the	   body	   to	   contribute	   to	   the	   formation	   of	   a	  plethora	   of	   different	   tissues	   and	   cell	   types,	   including	   melanocytes	   (5).	  Knowledge	   of	   neural	   crest	   cell	   biology	   might	   help	   to	   understand	   the	   basic	  mechanisms	   underlying	   growth	   and	   metastasis	   of	   cancers	   originating	   from	  neural	   crest	   derivatives,	   such	   as	   melanoma.	   Indeed,	   melanoma-­‐initiating	   cells	  have	  been	  reported	  to	  express	  the	  neural	  crest	  stem	  cell	  marker	  p75NTR/CD271	  (low	   affinity	   neurotrophin	   receptor)	   while	   lacking	   expression	   of	   markers	   of	  differentiated	   melanocytes,	   such	   as	   tyrosinase,	   melan-­‐A	   and	   melanoma-­‐associated	   antigen	   MAGE	   (6,	   7).	   Moreover,	   the	   neural	   crest	   stem	   cell	  transcription	   factor	   Sox10	  was	   recently	   shown	   to	   be	   expressed	   in	  mouse	   and	  human	  melanoma	  and	  to	  promote	  the	  formation	  and	  maintenance	  of	  melanoma	  (8).	   Taken	   together,	   these	   recent	   findings	   suggest	   that	   melanoma	   cells	   might	  utilize	  genetic	  and	  cellular	  programmes	  similar	  to	  embryonic	  neural	  crest	  stem	  cells.	  	  	  After	  emigration	  from	  the	  neural	  tube	  in	  culture,	  neural	  crest	  stem	  cells	  can	  be	  isolated	  and	  expanded	  in	  vitro	  as	  a	  monolayer	  of	  substrate-­‐attached	  multipotent	  cells	   (9,	   10).	   	  Moreover,	   neural	   crest	   cells	   can	   be	   propagated	   in	   vitro	   at	   clonal	  density	   allowing	   the	   investigation	   of	   multipotency	   at	   the	   single	   cell	   level.	  Undifferentiated,	   multipotent	   neural	   crest	   stem	   cells	   are	   characterized	   by	   the	  








	  1. Hank’s	   Balanced	   Salt	   Solution	   (HBSS)	   without	   phenol	   red	   (Cat.	   No.	  14025-­‐092,	   Invitrogen,	   Life	   Technologies),	   Hank’s	   Balanced	   Salt	  Solution	   (HBSS)	   wihtout	   Ca2+	   and	   Mg2+	   (Cat.	   No.	   14170-­‐088,	  Invitrogen,	  Life	  Technologies).	  2. Phosphate	   Buffered	   Saline	   (PBS)	   pH	   7.4	   (1x)	   (Cat.	   No.	   10010-­‐015,	  Invitrogen,	  Life	  Technologies).	  	  3. Water,	   Double	   Processed	   Tissue	   Culture	   Water	   (Cat.	   No.	   W3500,	  Sigma).	  	  4. Penicillin	   and	   Streptomycin	   (Cat.	   No.	   15140-­‐122,	   Invitrogen,	   Life	  Technologies).	  5. Sterile	  cell	   culture	  plastic	  pipettes	   individually	  wrapped	  (2,	  5,	  10,	  25	  ml).	  6. Plasticware:	   cell	   culture	   dish	   (35	   mm	   x	   10	   mm)	   (Corning	  Incorporated,	  Corning.	  Cat.	  No.	  430165).	  	  7. Dispase	   I	   (neutral	   protease,	   grade	   I),	   10x	   approx.	   2	  mg	   (Cat.	   No.	   04	  942	  086	  001,	  Roche).	  8. Substrate	   coating:	   0.1	   %	   solution	   of	   fibronectin	   (Cat.	   No.	   F1141,	  Sigma).	  9. Syringe	  Driver	  Filter	  Unit,	  0.22	  µm	  (Cat.	  No.	  SLGPO33RS,	  Millex-­‐GP).	  10. 	  50	  ml	  of	  neural	  crest	  medium	  is	  composed	  of	  47.1	  ml	  of	  L15CO2,	  50	  mg	   BSA	   (1mg/ml),	   2	   ml	   of	   1:1:2,	   50	   µl	   insulin	   (5	   µg/ml),	   100	   µl	  putrescine	   (16	   µg/ml),	   10	   µl	   progesterone	   (20	   nM),	   15	   µl	   selenious	  acid	  (30	  nM),	  0.5	  µl	  dexamethasone,	  143	  µl	  glycerol,	  50	  µl	  vitamin	  E	  (5	  µg/ml),	   500	  µl	  Mix	   7,	   20	   µl	   bFGF	   (10	  ng/ml)	   and	  100	  µl	   transferrin	  (100	  µg/ml).	  11. To	  prepare	  L15CO2,	  mix	  3.675	  g	  of	  Leibovitz’s	  L-­‐15	  powder	  (Cat.	  No.	  41300-­‐021,	  Invitrogen,	  Life	  Technologies),	  0.019	  g	  imidazole	  (Cat.	  No.	  I-­‐0250,	   Sigma),	   1.6	   ml	   of	   stable	   vitamin	   mix	   and	   288	   ml	   of	   water.	  Adjust	  pH	  to	  7.4.	  Separately,	  mix	  0.8	  g	  sodium	  bicarbonate	  (Cat.	  No.	  S-­‐5761,	  Sigma),	  120	  µl	  phenol	   red,	  59	  ml	  of	  water	  and	  apply	  CO2	  until	  the	  solution	  turns	  yellow.	  Add	  sodium	  bicarbonate	  solution	  and	  repeat	  CO2	  step.	  Store	  at	  40	  C.	  	  12. To	   prepare	   stable	   vitamin	   mix,	   mix	   0.6	   g	   aspartic	   acid	   (Cat.	   No.	   A-­‐4534,	  Sigma),	  0.6	  g	  L-­‐glutamic	  acid	  (Cat.	  No.	  G-­‐8415,	  Sigma),	  0.6	  g	  L-­‐proline	   (Cat.	   No.	   P-­‐4655,	   Sigma),	   0.6	   g	   L-­‐cysteine	   (Cat.	   No.	   C-­‐7602,	  Sigma),	  0.2	  g	  p-­‐aminobenzoic	  acid	  (Cat.	  No.	  42,976-­‐7,	  Aldrich),	  0.2	  g	  3-­‐aminoproprionic	   acid	   (Cat.	   No.	   A-­‐9920,	   Sigma),	   80	   mg	   vitamin	   B12	  (Cat.	  No.	  V-­‐6629,	  Sigma),	  0.4	  g	  myo-­‐inositol	   (Cat.	  No.	   I-­‐7508,	  Sigma),	  0.4	  g	  choline	  chloride	  (Cat.	  No.	  C-­‐7527,	  Sigma),	  1	  g	  fumaric	  acid	  (Cat.	  No.	   F-­‐8509,	   Sigma),	   16	   mg	   coenzyme	   A	   (Cat.	   No.	   C-­‐4282,	   Sigma)	  (solution	   1).	   Separately,	   dissolve	   0.4	   mg	   D-­‐biotin	   (Cat.	   No.	   B-­‐4639,	  Sigma)	  and	  100	  mg	  DL-­‐α-­‐lipoic	  acid	  (Cat.	  No.	  T-­‐1395,	  Sigma)	  in	  10	  ml	  of	  water	   (solution	   2).	   Add	   2	  ml	   of	   solution	   2	   to	   solution	   1,	  mix	   and	  prepare	  1.5	  ml	  aliquots.	  	  13. To	  prepare	  1:1:2,	   dissolve	  60	  g	  dextrose	   (Cat.	  No.	  G-­‐7021,	   Sigma)	   in	  160	   ml	   of	   water	   (adjust	   the	   volume	   to	   200	   ml	   after	   dextrose	   is	  dissolved).	  Add	  100	  ml	  glutamine	  (Cat.	  No.	  G-­‐6392,	  Sigma)	  (200	  mM)	  





	   1. Isolate	  E9.5	   embryos	   from	   the	  uterus	  of	   time-­‐mated	   females	   and	  place	  them	  into	  10-­‐cm	  petri	  dish	  with	  sterile	  HBSS	  without	  phenol	  red.	  From	  this	  step	  onwards,	  embryos	  and	  tissue	  should	  be	  stored	  on	  ice.	  2. Dissect	   the	   trunks	   and	   place	   them	   into	   a	   new	   3.5	   cm	   dish	  containing	   HBSS	   without	   phenol	   red.	   Prepare	   a	   mixture	   for	  enzymatic	  digestion.	  For	  this,	  dissolve	  1	  vial	  of	  Dispase	  I	  into	  12	  ml	  of	  HBSS	  (without	  Ca2+	  	  and	  Mg2+).	  	  Add	  12	  ml	  of	  dissolved	  Dispase	  I	  
into	  6	  well	  plate	  (2	  ml	  per	  each	  well)	  and	  transfer	  the	  trunks	  into	  this	  mixture	  for	  5	  min	  at	  4O	  C	  using	  a	  Pasteur	  pipette.	  	  3. In	  order	  to	  isolate	  neural	  tubes,	  carefully	  triturate	  the	  trunks	  using	  a	  Pasteur	  pipette.	  After	   the	   trituration	  step,	   transfer	  neural	   tubes	  into	   DMEM	   media	   supplemented	   with	   10%	   FCS	   to	   stop	   the	  enzymatic	   digestion	   step	   (at	   this	   step	   one	   can	   collect	   all	   neural	  tubes	  again	  in	  one	  3.5	  cm	  petri	  dish).	  4. Prepare	   3.5	   cm	   petri	   dishes	   for	   culturing:	   coat	   every	   3.5	   cm	  (Corning	   petri	   dish)	  with	   fibronectin.	   Add	   1	  ml	   of	   culture	  media	  into	   3.5	   cm	   dishes	   and	   place	   tissue	   culture	   dishes	   into	   the	   cell	  culture	  incubator.	  5. Plating	  of	  neural	  tubes:	  remove	  media	  (by	  leaving	  around	  200	  µl)	  and	  place	  carefully	  neural	  tube	  on	  the	  bottom	  of	  3.5	  cm	  plate	  (we	  usually	  plate	  2-­‐3	  neural	  tubes	  per	  dish).	  This	  step	  has	  to	  be	  done	  under	   the	   dissecting	   microscope.	   Try	   to	   avoid	   producing	   air	  bubbles	   as	   in	   this	   case,	   neural	   tubes	   will	   not	   attach.	   Use	   20	   µl	  Gilson	  pipette	  at	  this	  step.	  6. After	   30	   minutes	   of	   incubation	   at	   370	   C	   in	   the	   CO2	   incubator,	  carefully	   add	   the	   remaining	   media	   (removed	   at	   step	   5	   and	  collected	  into	  50	  ml	  tube)	  by	  controlling	  whether	  neural	  tubes	  are	  still	  attached.	  	  7. Incubate	  the	  neural	  crest	  explants	  at	  370	  C	  with	  5%	  humidified	  CO2	  for	   20	   hours	   to	   allow	   neural	   crest	   cells	   to	   emigrate	   from	   neural	  tube	  onto	  the	  plastic	  dish.	  Examine	  neural	  crest	  explants	  by	  phase	  microscopy.	  8. To	   initiate	   melanocyte	   differentiation,	   remove	   neural	   crest	  medium	  and	  add	  melanocyte	  medium	  (see	  components	  above).	  9. Medium	   should	   be	   changed	   every	   3	   days	   until	   appearance	   of	  visible	  pigmented	  cells.	  	  	  
4. Notes	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Figure	   1.	  A	   shematic	   representation	  of	   a	   protocol	   of	   in	   vitro	   derivation	  of	  
melanocytes	   from	   embryonic	   neural	   crest	   stem	   cells.	   In	   the	   first	   step,	   a	  neural	   tube	   is	   isolated	   from	   the	  mouse	   embryo	   at	   the	   embryonic	   day	   9.5	   and	  plated	  onto	  the	  culture	  dish,	  previously	  coated	  with	  fibronectin.	  After	  20	  hours	  of	   incubation,	   a	   population	   of	   undifferentated	   neural	   crest	   stem	   cells	   emigrate	  from	  the	  neural	  tube	  onto	  fibronectin-­‐coated	  surface.	   In	  the	  second	  step	  of	  this	  protocol,	   neural	   crest	   stem	   cells	   can	   be	   stimulated	   to	   acquire	   melanocytic	  differentiation	   by	   the	   addition	   of	   culture	   media	   containing	   specific	   growth	  factors.	   NT,	   neural	   tube.	   ET-­‐3,	   endothelin-­‐3.	   mSCF,	   mouse	   stem	   cell	   factor.	  α-­‐MSH,	   alpha-­‐melanocyte-­‐stimulating	  hormone.	  TPA,	   12-­‐O-­‐tetradecanoylphorbol-­‐13-­‐acetate.	  Dex,	  dexamethasone.	  FGF2,	  basic	  fibroblast	  growth	  factor.	  	  	  Figure	  2.	  An	  example	  of	  melanocytes	  derived	  from	  embryonic	  neural	  crest	  
stem	  cells.	  After	  10	  days	  of	  culture	  (media	  has	  to	  be	  refreshed	  every	  2-­‐3	  days)	  in	  melanocyte	  media	   supplemented	  with	  specific	  growth	   factors,	  one	  can	  observe	  an	   increasing	   number	   of	   pigmented	   cells.	   These	   cells	   can	   be	   easily	   visualized	  using	  bright	  field	  microscope.	  	  	  	  Figure	   3.	   Requirement	   of	   specific	   growth	   factors	   for	   the	   melanocytic	  
differentation.	  Only	  the	  specific	  growth	  factors	  (ET-­‐3,	  mSCF,	  α-­‐MSH,	  TPA,	  Dex,	  FGF2)	   can	   support	   the	   acquisition	   and	   survival	   of	   the	   melanocytic	  differentiation.	  FCS	  alone	  is	  not	  sufficient	  to	  drive	  the	  melanocytic	  differentation	  from	  the	  embryonic	  neural	  crest	  stem	  cells.	  FCS,	  fetal	  calf	  serum.	  	  	  	  



